James Q. Del Rosso, DO, and Neal Bhatia, MD, discuss the role of topical and oral JAK inhibitors in inflammatory disease management.
February 7th 2022
James Q. Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.
February 14th 2022
A review of topical JAK inhibitor ruxolitinib.
February 21st 2022
Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.
February 28th 2022
Drs James Q. Del Rosso and Neal Bhatia explain how to manage patients who fail therapy and provide safety considerations when treating those patients.